Date published: 2026-3-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

Eps8 Inhibitors

Eps8 inhibitors represent a specialized category of chemical agents designed to exert their effects on the Eps8 protein, a crucial component of intracellular signaling and cellular architecture. The Eps8 protein is known to be intricately involved in orchestrating actin cytoskeleton dynamics, which are fundamental for a wide array of cellular processes, such as cell motility, adhesion, and shape maintenance. These inhibitors are meticulously crafted molecules that function by selectively interacting with specific regions of the Eps8 protein, often its active sites or binding domains. This interaction disrupts the protein's ability to interact with other cellular partners, leading to downstream effects on various cellular pathways. Eps8 inhibitors are meticulously crafted molecules that function by selectively interacting with specific regions of the Eps8 protein, often its active sites or binding domains. This interaction disrupts the protein's ability to interact with other cellular partners, leading to downstream effects on various cellular pathways. The development of Eps8 inhibitors necessitates a comprehensive understanding of the protein's three-dimensional structure and its role in cellular function. Researchers employ various techniques, including computational modeling and structural biology, to uncover the critical sites within the protein that can be targeted by these inhibitors. By binding to these sites, Eps8 inhibitors alter the conformational dynamics of the protein, impairing its ability to associate with other signaling molecules or to regulate actin filament assembly effectively. The intricate mechanisms that Eps8 inhibitors influence have broader implications for cellular physiology. As the actin cytoskeleton is pivotal for cellular processes like cell migration, tissue development, and cellular response to external cues, the disruption of Eps8-mediated pathways through inhibitors can have wide-ranging effects on cellular behavior. Studying the effects of these inhibitors provides valuable insights into the intricate regulatory networks that govern cellular activities dependent on Eps8-mediated signaling.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

A first-generation EGFR TKI used for NSCLC by competing with ATP for EGFR kinase binding.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Another first-generation EGFR TKI inhibiting EGFR kinase activity, approved for NSCLC and pancreatic cancer.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

A second-generation EGFR TKI that irreversibly binds EGFR kinase domain, approved for NSCLC.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

A third-generation EGFR TKI targeting mutated EGFR, effective against NSCLC.